Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Murat O. Arcasoy"'
Autor:
Jeremy G. Price, MD, PhD, Donna Niedzwiecki, PhD, Taofik Oyekunle, MS, Murat O. Arcasoy, MD, Colin E. Champ, MD, Chris R. Kelsey, MD, Joseph K. Salama, MD, Michael J. Moravan, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 4, Pp 100729- (2021)
Background: Osteolytic lesions are present in 75% of patients with multiple myeloma (MM) and frequently require palliation with radiation therapy (RT). Prior case series of patients with MM with bone pain undergoing palliative RT suggests doses ≥12
Externí odkaz:
https://doaj.org/article/ef4da5ce77854187842f6d08bac961d3
Publikováno v:
Case Reports in Transplantation, Vol 2021 (2021)
Immune thrombocytopenia is a consumptive coagulopathy that can be either idiopathic or associated with infectious or autoimmune etiologies. Here, we present a case of immune thrombocytopenia in the setting of acute liver failure due to coexisting dia
Externí odkaz:
https://doaj.org/article/aa0debf0f99e46a7a9ebe05620d581f2
Autor:
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark Jones, Deanna Kornacki, Kang Sun, Hagop Kantarjian, for the COMFORT-I investigators
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-14 (2017)
Abstract Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I
Externí odkaz:
https://doaj.org/article/7414efd9cbe24affac81f3167f71f9d0
Autor:
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, Victor Sandor, Hagop Kantarjian
Publikováno v:
Haematologica, Vol 100, Iss 4 (2015)
In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to place
Externí odkaz:
https://doaj.org/article/7b14e5f72f2a48e1a0c3dbba240ffc5c
Autor:
Ruben A. Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard Levy, Andres Siulnik, Vikas Gupta, Mahmudul Khan, John F. DiPersio, Mari McQuitty, John V. Catalano, Deborah S. Hunter, Laurent Knoops, Michael Deininger, Francisco Cervantes, Carole Miller, Alessandro M. Vannucchi, Richard T. Silver, Tiziano Barbui, Moshe Talpaz, Giovanni Barosi, Elliott F. Winton, Estella Mendeson, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, William Sun, Victor Sandor, Hagop M. Kantarjian, Claire Harrison
Publikováno v:
Haematologica, Vol 99, Iss 2 (2014)
Prior to Janus kinase inhibitors, available therapies for myelofibrosis were generally supportive and did not improve survival. This analysis compares efficacy outcomes of patients with myelofibrosis in the control arms (placebo [n=154] and best avai
Externí odkaz:
https://doaj.org/article/23c64710c3624182a69371f30b69787f
Autor:
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson-Viitanen, William Sun, Victor Sandor, Hagop M. Kantarjian
Publikováno v:
Haematologica, Vol 98, Iss 12 (2013)
COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis. This analysis of COMFORT-I describes the long-term efficacy a
Externí odkaz:
https://doaj.org/article/eb6fdd88d68b49a881699bb335455fab
Autor:
Murat O. Arcasoy
Publikováno v:
Haematologica, Vol 95, Iss 11 (2010)
Externí odkaz:
https://doaj.org/article/e06816ffbe7d4618ad7237fe9d907011
Autor:
Deanna Kornacki, Moshe Talpaz, Josef T. Prchal, Jason Clark, Srdan Verstovsek, Solomon I. Hamburg, Philomena Colucci, Murat O. Arcasoy, Lawrence B. Afrin
Publikováno v:
Clinical lymphoma, myeloma & leukemia, vol 22, iss 5
Introduction : Treatment options in patients with myelofibrosis (MF) presenting with thrombocytopenia are limited. Final results of the phase 2 study (NCT01348490) of ruxolitinib in patients with MF and low baseline platelet counts (50–100 × 109/L
Autor:
C. Conover Talbot, Byunghak Kang, Elizabeth W. Pugh, Dustin L. Gable, Cory Brayton, Nuria Amat-Codina, Liliana Florea, Kara M. Schenk, Christine C. Atik, Mary Armanios, Murat O. Arcasoy, Susan E. Stanley, Valeriya Gaysinskaya
Publikováno v:
Genes & Development. 33:1381-1396
Short telomere syndromes manifest as familial idiopathic pulmonary fibrosis; they are the most common premature aging disorders. We used genome-wide linkage to identify heterozygous loss of function of ZCCHC8, a zinc-knuckle containing protein, as a
Autor:
John Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N. Harrison, Mary Frances McMullin, Alessandro M. Vannucchi, Joanne Ewing, Casey L. O'Connell, Jean-Jacques Kiladjian, Adam J. Mead, Elliott F. Winton, David S. Leibowitz, Valerio De Stefano, Murat O. Arcasoy, Craig M. Kessler, Rosalind Catchatourian, Damiano Rondelli, Richard T. Silver, Andrea Bacigalupo, Arnon Nagler, Marina Kremyanskaya, Max F. Levine, Juan E. Arango Ossa, Erin McGovern, Lonette Sandy, Mohamad E. Salama, Vesna Najfeld, Joseph Tripodi, Noushin Farnoud, Alexander V. Penson, Rona Singer Weinberg, Leah Price, Judith D. Goldberg, Tiziano Barbui, Roberto Marchioli, Gianni Tognoni, Raajit K. Rampal, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman
Publikováno v:
Mascarenhas, J, Kosiorek, H E, Prchal, J T, Rambaldi, A, Berenzon, D, Yacoub, A, Harrison, C N, McMullin, M F F, Vannucchi, A M, Ewing, J, O'Connell, C L, Kiladjian, J-J, Mead, A J, Winton, E F, Leibowitz, D S, De Stefano, V, Arcasoy, M O, Kessler, C M, Catchatourian, R, Rondelli, D, Silver, R T, Bacigalupo, A, Nagler, A, Kremyanskaya, M, Levine, M F, Arango Ossa, J E, McGovern, E M, Sandy, L, Salama, M E, Najfeld, V, Tripodi, J, Farnoud, N, Penson, A V, Weinberg, R S, Price, L, Goldberg, J D, Barbui, T, Marchioli, R, Tognoni, G, Rampal, R K, Mesa, R A, Dueck, A C & Hoffman, R 2022, ' A Randomized, Phase 3, Trial of Interferon-α versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia ', Blood . https://doi.org/10.1182/blood.2021012743
The goal of therapy for essential thrombocythemia (ET) and polycythemia vera (PV) patients is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for